This review concluded that the use of aspirin for the prevention of cardiac events needed to be weighed against an increase in major bleeds. There was no justification in advocating the routine use of aspirin. Despite some concerns, the analyses contained a large number of people and the results seemed consistent. The conservative conclusions were likely to be reliable.
Authors' objectives
To evaluate the prevention of cardiovascular events and incidence of major bleeding associated with the use of lowdose aspirin in patients with or without a prior history of vascular disease.
Searching
MEDLINE, EMBASE, Derwent, SciSearch and BIOSIS Previews were searched; search terms and dates were not reported. Relevant journals, abstracts and conference proceedings were handsearched. The reference lists of included studies and reviews were scanned and colleagues contacted, including representatives from pharmaceutical companies. (This information was supplied on request by the lead author.)
Study selection
Randomised trials comparing aspirin with no aspirin where no other antiplatelet drug was administered were eligible for inclusion. Primary prevention trials had to recruit at least 1,000 non-diabetic patients without a history of occlusive disease and provide at least two years scheduled treatment. Secondary prevention trials had to include patients with previous myocardial infarction, stroke or trans-ischaemic attacks. The primary outcomes were myocardial infarction, stroke, trans-ischaemic attacks, all-cause and cardiovascular death, and major extracranial bleeding. Where reported, participants were mostly men. Mean age ranged from 53 to 68 years. The proportion with diabetes ranged from two per cent to 23 per cent, hypertension 10 per cent to 100 per cent and vascular disease less than one per cent to eight per cent in primary prevention trials and 100 per cent in secondary prevention trials. Aspirin dose ranged from 100 mg on alternate days to 500 mg daily. The authors did not state how many reviewers performed the study selection.
Assessment of study quality
The authors did not report any validation or checking of the data used in the analyses.
Data extraction
Individual patient data were obtained for the incidence of the outcomes of interest; rate ratios of yearly events for aspirin/no aspirin and 99% confidence intervals (CI) were calculated for each study. For trials with unequal randomisation, the control group was multiplied to be comparable in size to the intervention group and control totals were adjusted.
Methods of synthesis
Pooled rate ratios with 95% CI were calculated (the method used was not reported). The X 2 test was used to test heterogeneity. Poisson regression stratified by trial was used to identify risk factors for cardiovascular outcomes and major bleeding, and to predict five-year absolute effects of aspirin in patients with different risks of coronary heart disease.
Results of the review
Twenty two trials met the inclusion criteria (n=112,485; range 60 to 39,876): six primary prevention trials (n=95,456) and 16 secondary prevention trials (n=17,029).
In the six primary prevention trials, the rate of serious vascular events was 0.51 per cent per year with aspirin and 0.57 per cent per year without aspirin, representing a statistically significant 12 per cent proportional reduction in occurrence
